Trade Report: Today: Halozyme Therapeutics Inc. (HALO) Stake Raised by First Eagle Investment Management LLC

Today: Halozyme Therapeutics Inc. (HALO) Stake Raised by First Eagle Investment Management LLC

First Eagle Investment Management LLC raised its position in Halozyme Therapeutics Inc. (NASDAQ:HALO) by 4.1% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,395,500 shares of the biopharmaceutical company’s stock after buying an additional 294,500 shares during the period. First Eagle Investment Management LLC owned approximately 5.78% of Halozyme Therapeutics worth $89,338,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in HALO. M&T Bank Corp raised its position in Halozyme Therapeutics by 14.5% in the second quarter. M&T Bank Corp now owns 36,738 shares of the biopharmaceutical company’s stock worth $317,000 after buying an additional 4,657 shares during the period. DekaBank Deutsche Girozentrale raised its position in Halozyme Therapeutics by 8.1% in the second quarter. DekaBank Deutsche Girozentrale now owns 66,700 shares of the biopharmaceutical company’s stock worth $562,000 after buying an additional 5,000 shares during the period. IFC Holdings Incorporated FL raised its position in Halozyme Therapeutics by 6.2% in the second quarter. IFC Holdings Incorporated FL now owns 95,500 shares of the biopharmaceutical company’s stock worth $885,000 after buying an additional 5,600 shares during the period. California State Teachers Retirement System raised its position in Halozyme Therapeutics by 1.4% in the second quarter. California State Teachers Retirement System now owns 228,638 shares of the biopharmaceutical company’s stock worth $1,973,000 after buying an additional 3,260 shares during the period. Finally, Bank of New York Mellon Corp raised its position in Halozyme Therapeutics by 359.0% in the second quarter. Bank of New York Mellon Corp now owns 2,279,701 shares of the biopharmaceutical company’s stock worth $19,674,000 after buying an additional 1,783,067 shares during the period. 81.10% of the stock is owned by hedge funds and other institutional investors.

Shares of Halozyme Therapeutics Inc. (NASDAQ:HALO) opened at 12.99 on Monday. The stock’s market capitalization is $1.66 billion. Halozyme Therapeutics Inc. has a 12 month low of $6.96 and a 12 month high of $18.39. The firm’s 50-day moving average price is $10.70 and its 200-day moving average price is $10.10.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings data on Monday, November 7th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.27) by $0.04. The business earned $31.90 million during the quarter, compared to analyst estimates of $34.43 million. Halozyme Therapeutics had a negative return on equity of 405.28% and a negative net margin of 44.60%. The company’s revenue was up 53.4% on a year-over-year basis. During the same quarter last year, the business posted ($0.19) EPS. On average, equities research analysts forecast that Halozyme Therapeutics Inc. will post ($0.87) EPS for the current year.

A number of research firms have recently weighed in on HALO. Piper Jaffray Cos. upped their price objective on Halozyme Therapeutics from $15.00 to $18.00 and gave the stock an “overweight” rating in a research note on Friday, September 16th. Wells Fargo & Co. reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research note on Thursday, September 8th. Jefferies Group reaffirmed a “sell” rating and issued a $6.75 price objective on shares of Halozyme Therapeutics in a research note on Tuesday, November 8th. Finally, Deutsche Bank AG started coverage on Halozyme Therapeutics in a research note on Thursday, November 3rd. They issued a “buy” rating and a $12.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $13.96.

About Halozyme Therapeutics

Related posts

Leave a Comment